Nancy A Simonian Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Nancy A Simonian.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Nancy A Simonian. Nancy A Simonian is a Director in ARQULE INC ($ARQL) and a Director in SEATTLE GENETICS INC /WA ($SGEN) and a President & CEO in Syros Pharmaceuticals, Inc. ($SYRS) and a President and CEO in Syros Pharmaceuticals, Inc. ($SYRS) and a Director in Evelo Biosciences, Inc. ($EVLO).
Address: C/O ARQULE, INC. 19 PRESIDENTIAL WAY WOBURN 01801 MA
Companies in which Nancy A Simonian is an Insider
ARQULE INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Nancy A Simonian: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: May 17 2010
$ARQL Market Capitalization: $96.01M
$ARQL Previous Close: $1.37
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Evelo Biosciences, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Nancy A Simonian: Director
Holdings: 0 shares
Latest Transaction: Jun 18 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Seagen Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Nancy A Simonian: Director
Holdings: 26,098 shares
Current Value: $1,586,497
Latest Transaction: May 19 2020
$SGEN Market Capitalization: $8.71B
$SGEN Previous Close: $60.79
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Syros Pharmaceuticals, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Nancy A Simonian: President & CEO, President and CEO
Holdings: 544,450 shares
Current Value: $5,945,394
Latest Transaction: Feb 19 2021
$SYRS Market Capitalization: $249.93M
$SYRS Previous Close: $10.92
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Nancy A Simonian
Sentiment: All, ARQL, EVLO, SGEN, SYRS
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19 2021 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Option Exercise | A | 11.41 | 304,000 | 3,468,640 | 304,000 | |
| Dec 21 2020 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Option Exercise | M | 10.09 | 4,988 | 50,329 | 280,012 | |
| Dec 21 2020 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Option Exercise | M | 8.51 | 14,168 | 120,570 | 79,165 | |
| Dec 21 2020 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Option Exercise | M | 3.04 | 10,761 | 32,713 | 21,524 | |
| Dec 21 2020 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Buy | M | 10.09 | 4,988 | 50,329 | 563,606 | 558.6 K to 563.6 K (+0.89 %) |
| Dec 21 2020 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Buy | M | 8.51 | 14,168 | 120,570 | 558,618 | 544.5 K to 558.6 K (+2.60 %) |
| Dec 21 2020 | SYRS | Syros Pharmaceutic ... | Simonian Nancy A | President & CEO | Buy | M | 3.04 | 10,761 | 32,713 | 544,450 | 533.7 K to 544.5 K (+2.02 %) |